HDMA design, preparation, and application has incorporate a proton acceptor in the carbocation skeleton, generating a novel immonium salts.
HDMA is a peptide coupling agent with increased coupling efficiency and lower racemization compared to HATU.
HDMA is a registered patent of Luxembourg Bio Technologies (No. 101784522/8,524,898).

CAS: 958029-37-3

Synonym: 1-[(Dimethylamino)(morpholino)methylene]-1H-[1,2,3]triazolo[4,5-b]pyridine-1-ium 3-oxidehexafluorophosphate




Molecular Formula


Molecular Weight

422.3 gr/mol


White to off-white crystalline powder

Storage Conditions

store in a cool and dry place (2-8oC)


  • HDMA present enhanced solubility (due to the oxygen atom in the carbon skeleton), which is the first property to be taken into account, having it’s great influence on the reaction yield and its performance in the automatic synthesizers.
    This enhanced solubility should help the removal of urea in the workup stage, formed during the coupling in a solution mode approach.
  • Couplings involving immonium salts, such as HDMA are carried out with an excess of base, at least 2 equiv., in this regard, coupling reactions carried out with HDAMA allowing the use of just 1 equiv. of base. This fact has great importance on the economical savings in the production of bulk quantities of peptides.


  • Novel Proton Acceptor Immonium-Type Coupling Reagents: Application in Solution and Solid-Phase Peptide Synthesis 
    A. El-Faham and F. Albericio Org. Lett., 2007, 9 (22), pp 4475–4477.
    Read Article

Request an Information or Quotation